Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Pitolisant (Primary)
- Indications Hypersomnia
- Focus Therapeutic Use
- Acronyms HAROSA IV
- Sponsors Bioprojet
- 22 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 22 Nov 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2017.
- 22 Nov 2017 Planned initiation date changed from 1 Jan 2017 to NULL.